Infinimmune, Merck enter into antibody discovery pact

By Kunal Das

March 31 (Reuters) – Biotech firm Infinimmune said on Tuesday it has entered into a deal with drugmaker ​Merck that could be worth up to ‌about $838 million in milestone payments, to discover and develop multiple antibodies for various undisclosed diseases.

(Reporting by Kunal Das in Bengaluru; Editing by Shailesh Kuber and ​Sahal Muhammed)